Business · 23/05/2017Updated: 10/17/2026 · 1 min read
FDA Requests Public Comment on Proposed Collection of Information for Drug and Biological Product User Fee Waivers, Reductions, and Refunds
Summary
The Food and Drug Administration (FDA) is seeking public input on proposed changes to its user fee waiver, reduction, and refund policies for drug and biological products, as required by the Paperwork Reduction Act of 1995.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →